A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Latest Information Update: 01 Jul 2024
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms EXAMINER
- Sponsors Exelixis
- 26 Jan 2024 This trail has been completed in France according to European Clinical Trials Database record.
- 23 Jan 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 01 May 2022 Primary endpoint has not been met. (Progression Free Survival), as per Results published in the Thyroid